Brief: Alpine Immune Sciences Announces Amendment Of Acazicolcept Option And License Agreement With Abbvie

Alpine Immune Sciences

21/12/2023 22:29

Dec 21 (Reuters) - Alpine Immune Sciences Inc  ALPN.O :
    * ALPINE IMMUNE SCIENCES ANNOUNCES AMENDMENT OF ACAZICOLCEPT
OPTION AND LICENSE AGREEMENT WITH ABBVIE
    * ALPINE IMMUNE SCIENCES INC - FINAL ANALYSIS AFTER LAST
PATIENT
COMPLETES STUDY PROTOCOL EXPECTED TO OCCUR BY END OF 2024
    * ALPINE IMMUNE SCIENCES - PREVIOUSLY DISCLOSED OPTION
EXERCISE
FEE OF $75 MILLION REDUCED TO $10 MILLION AND REMAINING
PRE-OPTION DEVELOPMENT MILESTONE REMOVED
    * ALPINE IMMUNE SCIENCES- CO TO STOP ENROLLMENT UNDER
AMENDED
AGREEMENT IN PHASE 2 STUDY OF ACAZICOLCEPT IN SYSTEMIC LUPUS
ERYTHEMATOSUS WITHIN 30 DAYS
    * ALPINE IMMUNE SCIENCES- UNDER AMENDMENT, POTENTIAL FUTURE
DEVELOPMENT, COMMERCIAL, & SALES-BASED MILESTONES AND
SALES-BASED ROYALTIES REDUCED BY 25%

Source text for Eikon:  ID:nBw3t2kksa 
Further company coverage:  ALPN.O 

 ((Reuters.Briefs@thomsonreuters.com;))